# China NMPA Drug Inspection - Sichuan Pharmaceutical Co., Ltd. - Magnolia officinalis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-pharmaceutical-co-ltd/2683fe58-63b6-4456-84ef-8bdfe22732c0/
Source feed: China

> China NMPA drug inspection for Sichuan Pharmaceutical Co., Ltd. published April 03, 2018. Drug: Magnolia officinalis. The Chongqing Municipal Food and Drug Administration issued its 2018 Issue 1 Drug Quality Announcement on April 3, 2018,

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Food and Drug Administration's Drug Quality Bulletin, Issue 1, 2018
- Company Name: Sichuan Pharmaceutical Co., Ltd.
- Publication Date: 2018-04-03
- Drug Name: Magnolia officinalis
- Inspection Finding: Content determination
- Summary: The Chongqing Municipal Food and Drug Administration issued its 2018 Issue 1 Drug Quality Announcement on April 3, 2018, following a city-wide sampling inspection. The objective was to strengthen drug quality supervision, regulate market order, and ensure public drug safety. The inspection identified numerous non-compliant drug products from several pharmaceutical companies, primarily traditional Chinese medicine pieces. Key manufacturers implicated include Sichuan Longfa Pharmaceutical Co., Ltd., Sichuan Zhongyong Pharmaceutical Co., Ltd., Bozhou City Traditional Chinese Medicine Slices Factory, Anhui Haixin Traditional Chinese Medicine Pieces Co., Ltd., and others such as Sichuan Zining, Sichuan Qianfang, and Chongqing Zigong Pharmaceutical. Violations were diverse, frequently citing failures to meet standards outlined in the Chinese Pharmacopoeia (various editions from 2005 to 2015) and supplementary testing approvals. Common issues involved discrepancies in "Content Determination" for active ingredients, non-conformance in "Properties," "Identification," or "Microscopic Features." Additionally, several products failed "Inspection" criteria related to impurities like magnesium salts, aluminum salts, total ash, and sulfur dioxide residue, or exhibited incorrect "Appearance" and "Characteristics." This announcement serves as a public notification of these quality failures, indicating the need for regulatory action against the identified manufacturers to ensure product integrity and public health.

Company: https://www.globalkeysolutions.net/companies/sichuan-pharmaceutical-co-ltd/73053b74-f673-40ef-ae8b-f01e72e92784/